Hyperfine (HYPR) Net Income towards Common Stockholders Growth (3y) (2024 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 29.56% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Hyperfine | 149.47 Mn | 108.20 Mn | 1.98 Mn | 10.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.83% |
| Dec 31, 2025 | 23.22% |
| Sep 30, 2025 | 5.77% |
| Jun 30, 2025 | 26.42% |
| Mar 31, 2025 | 26.56% |
| Dec 31, 2024 | 26.42% |
| Sep 30, 2024 | 14.28% |
| Jun 30, 2024 | 11.35% |
| Mar 31, 2024 | -8.11% |